Söndag 25 Januari | 06:08:34 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-08-20 08:30 Kvartalsrapport 2026-Q2
2026-05-07 N/A Årsstämma
2026-05-07 08:30 Kvartalsrapport 2026-Q1
2026-02-20 08:30 Bokslutskommuniké 2025
2026-01-20 - Extra Bolagsstämma 2026
2025-11-27 - Kvartalsrapport 2025-Q3
2025-10-10 - Extra Bolagsstämma 2025
2025-08-11 - Kvartalsrapport 2025-Q2
2025-05-08 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2025-05-07 - Årsstämma
2025-05-07 - Kvartalsrapport 2025-Q1
2025-02-20 - Bokslutskommuniké 2024
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-08 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2024-05-07 - Årsstämma
2024-05-07 - Kvartalsrapport 2024-Q1
2024-02-22 - Bokslutskommuniké 2023
2023-10-31 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2023-05-25 - Årsstämma
2023-05-03 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-02 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-30 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2022-05-27 - Årsstämma
2022-05-06 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-24 - Extra Bolagsstämma 2021
2021-10-20 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2021-05-27 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-03 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2020-05-27 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-17 - Bokslutskommuniké 2019
2019-10-31 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-06-04 - Årsstämma
2019-05-23 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2019-04-30 - Kvartalsrapport 2019-Q1
2019-02-15 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriMedicinteknik
Lumito är ett svenskt bolag som utvecklar och marknadsför system för vävnads- och biomarköranalys inom digital patologi, byggda på uppkonverterande nanopartikelteknik. Bolaget riktar sig till vårdinrättningar, forskning och läkemedelssektorn. Bolaget bildades 2010 som en spinoff från en forskargrupp vid Lunds universitets avdelning för atomfysik och lasercentrum. Lumito har sitt huvudkontor i Lund.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-01-23 14:50:00

Lumito AB (publ) (“Lumito” or the “Company”) today announces that its joint work together with Boston Cell Standards, was featured in a scientific poster presentation at the 2026 Winter Meeting of The Pathological Society of Great Britain & Ireland, which took place 20-21 January 2026.

The poster, authored and presented by Keith Miller, focuses on recent advances in HER2 calibrators (i.e., reference material containing a precisely known amount of HER2, enabling standardisation and comparability between laboratories) as well as novel slide-based technologies for HER2 labelling, developed through collaborative efforts between the teams in the United States and in Sweden. The initiative was driven by Keith who identified the work as highly relevant to the pathology community and of significant interest to laboratories seeking to further improve their immunohistochemistry (IHC) services.

The inclusion of this work at one of the UK and Ireland’s leading pathology meetings underscores the growing international interest and market pull for standardised, high-quality solutions in HER2 testing. The same can be applied to companion diagnostics such as PD-L1 and Oestrogen Receptor

”My aim with this poster was to showcase the important and complementary work being carried out on both sides of the Atlantic. There is clear demand within the pathology community for robust IHC calibration tools and improvements in IHC labelling for critical companion diagnostics, such as those for HER2. These developments are absolutely essential, if IHC testing centres are to meet the ever-increasing standards required for patient care,”says Keith Miller, Honorary Associate Professor at the Research Department of Pathology, UCL Cancer Institute, London and honorary member of The Pathological Society of Great Britain & Ireland.

Miller, who spent four decades working in IHC, was the lead of the UK National External Quality Assessment Scheme for Immunocytochemistry and In-Situ Hybridisation. He was also founder of UCL-Advanced Diagnostics, a UK reference centre laboratory for IHC that is now under the Health Service Laboratories in London.

The poster provides an update on ongoing developments and serves to inform pathologists, laboratory managers and decision-makers about technologies that are already available, as well as innovations expected to reach the market in the near future.

The poster is available on Lumito’s website, here.